NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its quarterly earnings results on Thursday, November, 21st. The biotechnology company reported $0.44 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.56 by $0.12. The biotechnology company earned $51.30 million during the quarter, compared to the consensus estimate of $55.95 million. Enanta Pharmaceuticals had a return on equity of 10.46% and a net margin of 22.60%. The company's revenue was down 23.7% on a year-over-year basis. During the same period in the previous year, the firm posted $1.30 earnings per share. View Enanta Pharmaceuticals' Earnings History.

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Enanta Pharmaceuticals.

4 brokers have issued 12 month price objectives for Enanta Pharmaceuticals' stock. Their forecasts range from $57.00 to $130.00. On average, they expect Enanta Pharmaceuticals' stock price to reach $101.33 in the next twelve months. This suggests a possible upside of 84.7% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.

Media coverage about ENTA stock has been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Enanta Pharmaceuticals.

Enanta Pharmaceuticals saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 2,440,000 shares, an increase of 7.0% from the November 28th total of 2,280,000 shares. Based on an average daily trading volume, of 197,600 shares, the short-interest ratio is currently 12.3 days. Currently, 14.1% of the shares of the stock are short sold. View Enanta Pharmaceuticals' Current Options Chain.

Some companies that are related to Enanta Pharmaceuticals include Evotec (EVTCY), BridgeBio Pharma (BBIO), Allakos (ALLK), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Pandora Media (P), Ryder System (R), Tandem Diabetes Care (TNDM), NVIDIA (NVDA), Wells Fargo & Co (WFC), Ford Motor (F), Alibaba Group (BABA) and Tesla (TSLA).

Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Strs Ohio (0.06%), State of Alaska Department of Revenue (0.06%), Wedge Capital Management L L P NC (0.03%), Louisiana State Employees Retirement System (0.03%), Zurcher Kantonalbank Zurich Cantonalbank (0.01%) and Valeo Financial Advisors LLC (0.00%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, Valeo Financial Advisors LLC and State of Alaska Department of Revenue. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Bruce L A Carter, George Golumbeski, Nathaniel S Gardiner, Paul J Mellett and Yat Sun Or. View Insider Buying and Selling for Enanta Pharmaceuticals.

ENTA stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, Wedge Capital Management L L P NC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $54.85.

Enanta Pharmaceuticals has a market capitalization of $1.09 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.View Additional Information About Enanta Pharmaceuticals.

The official website for Enanta Pharmaceuticals is http://www.enanta.com/.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]